The Edinburgh Investment Trust plc Issues Warning From Woodford

The portfolio manager of the Edinburgh Investment Trust plc (LON: EDIN), Neil Woodford, sees lower returns during the next three years.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The shares of Edinburgh Investment Trust (LSE: EDIN) climbed 7p to 585p during early trade this morning despite the FTSE 250 member publishing half-year results that carried a warning from Neil Woodford.

Mr Woodford, who manages the portfolio owned by the Edinburgh trust through investment group Invesco Perpetual, cautioned that “returns over the next three years are likely to be somewhat lower than over the last three years, purely as a consequence of the higher valuations that we now see in our market.

He also claimed the withdrawal of “extraordinary” monetary policies in the US was “ultimately inevitable” and admitted he was worried about “the near-term implications of tapering” for equities.

While Mr Woodford added it was “more difficult than usual” to predict the path that the market could take over the next few months, he did reassure shareholders of the Edinburgh trust that their portfolio had “the potential to deliver an attractive positive return over more sensible, longer-time horizons.”

The trust’s half-year results showed the portfolio’s net assets advancing 2% to 592p per share with debt measured at par value.

Major holdings at the September half-year included Woodford favourites GlaxoSmithKline, AstraZeneca, BT, British American Tobacco and Roche.

Mr Woodford also took the opportunity to criticise recent political remarks about the utility sector.

Referring to the 20-month bill freeze proposed by the Labour Party, he described the economics of the policy as “absurd“.

Mr Woodford claimed:

We believe it is irrational for any privately-owned company to sell its products or services at a loss and we would encourage any company that was forced to do so to simply stop supplying.

Prices have not increased through company profiteering – there have been 20 separate inquiries into the energy market since 2001, none of which have found evidence of anti-competitive behaviour.

The Edinburgh trust has stakes in gas supplier Centrica and electricity generator SSE.

Last month Mr Woodford announced he would leave Invesco Perpetual in April to start his own fund-management business.

Jim Pettigrew, the chairman of the Edinburgh trust, said the board “would like to take some time to consider the options for the future management of the company before it makes a decision“.

Based on this morning’s share-price reaction, Edinburgh’s shares trade at about book value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Maynard does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

As summer ends, what’s next for the TUI share price?

With many travel companies still in recovery mode following the pandemic, can the TUI share price ever return to previous…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in September [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this FTSE 100 hospitality giant poised for a rebound?

Many companies on the FTSE 100 have a long history. But with this one now over 250 years old, I'm…

Read more »

Investing Articles

If I invest £5,000 in Greggs shares, how much passive income would I receive?

Greggs shares have delivered mouth-watering returns in recent years. Charlie Carman considers whether they're worth adding to a dividend portfolio…

Read more »

Investing Articles

History says I might regret not buying UK shares while they’re this cheap

This investor thinks UK shares continue to trade too cheaply, while falling interest rates make parts of the FTSE 250…

Read more »

Investing Articles

Looking for value shares? This FTSE 100 giant looks tempting to me!

Value shares represent an opportunity to snap up top stocks at a great entry point. This FTSE 100 pick looks…

Read more »

Investing Articles

Is the BP share price back in bargain territory?

The energy sector is at a critical juncture, and the BP share price is down in 2024. So is this…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

At 52-week lows, are these FTSE 100 value stocks now outstanding bargains?

A couple of value stocks having been grabbing our writer's attention. But could things get worse for them before they…

Read more »